Investigar	O
los	O
efectos	O
del	O
acetato	O
de	O
medroxiprogesterona	O
(	O
MPA	O
)	O
sobre	O
el	O
apetito	O
,	O
el	O
peso	O
y	O
la	O
calidad	O
de	O
vida	O
(	O
QL	O
)	O
en	O
pacientes	O
con	O
cáncer	O
en	O
etapa	O
avanzada	O
,	O
incurable	O
,	O
no	O
sensible	O
a	O
las	O
hormonas	O
.	O

Doscientos	O
seis	O
pacientes	O
elegibles	O
fueron	O
aleatorizados	O
entre	O
MPA	O
doble	O
ciego	O
500	O
mg	O
dos	O
veces	O
al	O
día	O
o	O
placebo	O
.	O

Se	O
evaluaron	O
el	O
apetito	O
(	O
escala	O
de	O
calificación	O
numérica	O
de	O
0	O
a	O
10	O
)	O
,	O
el	O
peso	O
y	O
la	O
QL	O
(	O
Cuestionario	O
de	O
calidad	O
de	O
vida	O
de	O
la	O
Organización	O
Europea	O
para	O
la	O
Investigación	O
y	O
el	O
Tratamiento	O
del	O
Cáncer	O
[	O
EORTC-QLQ-C30	O
]	O
)	O
antes	O
del	O
inicio	O
del	O
tratamiento	O
(	O
t	O
=	O
0	O
)	O
,	O
y	O
6	O
semanas	O
(	O
t	O
=	O
6	O
)	O
y	O
12	O
semanas	O
(	O
t	O
=	O
12	O
)	O
a	O
partir	O
de	O
entonces	O
.	O

Ciento	O
treinta	O
y	O
cuatro	O
pacientes	O
(	O
68	O
MPA	O
y	O
66	O
placebo	O
)	O
fueron	O
evaluables	O
en	O
t	O
=	O
6	O
y	O
99	O
pacientes	O
(	O
53	O
MPA	O
y	O
46	O
placebo	O
)	O
en	O
t	O
=	O
12	O
.	O

Se	B-Premise-Support-6
observó	I-Premise-Support-6
un	I-Premise-Support-6
efecto	I-Premise-Support-6
beneficioso	I-Premise-Support-6
del	I-Premise-Support-6
MPA	I-Premise-Support-6
sobre	I-Premise-Support-6
el	I-Premise-Support-6
apetito	I-Premise-Support-6
después	I-Premise-Support-6
de	I-Premise-Support-6
6	I-Premise-Support-6
semanas	I-Premise-Support-6
(	I-Premise-Support-6
P	I-Premise-Support-6
=	I-Premise-Support-6
0,008	I-Premise-Support-6
)	I-Premise-Support-6
y	I-Premise-Support-6
12	I-Premise-Support-6
semanas	I-Premise-Support-6
(	I-Premise-Support-6
P	I-Premise-Support-6
=	I-Premise-Support-6
0,01	I-Premise-Support-6
)	I-Premise-Support-6
de	I-Premise-Support-6
tratamiento	I-Premise-Support-6
.	I-Premise-Support-6

Después	B-Premise-Support-5
de	I-Premise-Support-5
12	I-Premise-Support-5
semanas	I-Premise-Support-5
,	I-Premise-Support-5
se	I-Premise-Support-5
observó	I-Premise-Support-5
un	I-Premise-Support-5
aumento	I-Premise-Support-5
de	I-Premise-Support-5
peso	I-Premise-Support-5
medio	I-Premise-Support-5
de	I-Premise-Support-5
0,6	I-Premise-Support-5
+/-	I-Premise-Support-5
4,4	I-Premise-Support-5
kg	I-Premise-Support-5
en	I-Premise-Support-5
el	I-Premise-Support-5
grupo	I-Premise-Support-5
MPA	I-Premise-Support-5
,	I-Premise-Support-5
frente	I-Premise-Support-5
a	I-Premise-Support-5
una	I-Premise-Support-5
pérdida	I-Premise-Support-5
de	I-Premise-Support-5
peso	I-Premise-Support-5
media	I-Premise-Support-5
constante	I-Premise-Support-5
de	I-Premise-Support-5
1,4	I-Premise-Support-5
+/-	I-Premise-Support-5
4,6	I-Premise-Support-5
kg	I-Premise-Support-5
en	I-Premise-Support-5
el	I-Premise-Support-5
grupo	I-Premise-Support-5
de	I-Premise-Support-5
placebo	I-Premise-Support-5
.	I-Premise-Support-5

Esta	B-Premise-Support--1
diferencia	I-Premise-Support--1
de	I-Premise-Support--1
2,0	I-Premise-Support--1
kg	I-Premise-Support--1
fue	I-Premise-Support--1
estadísticamente	I-Premise-Support--1
significativa	I-Premise-Support--1
(	I-Premise-Support--1
P	I-Premise-Support--1
=	I-Premise-Support--1
0,04	I-Premise-Support--1
)	I-Premise-Support--1
.	I-Premise-Support--1

Durante	B-Premise-Support-1
el	I-Premise-Support-1
estudio	I-Premise-Support-1
,	I-Premise-Support-1
varias	I-Premise-Support-1
áreas	I-Premise-Support-1
de	I-Premise-Support-1
calidad	I-Premise-Support-1
de	I-Premise-Support-1
vida	I-Premise-Support-1
se	I-Premise-Support-1
deterioraron	I-Premise-Support-1
en	I-Premise-Support-1
el	I-Premise-Support-1
grupo	I-Premise-Support-1
total	I-Premise-Support-1
de	I-Premise-Support-1
pacientes	I-Premise-Support-1
.	I-Premise-Support-1

Con	B-Claim-Support-3
la	I-Claim-Support-3
excepción	I-Claim-Support-3
de	I-Claim-Support-3
una	I-Claim-Support-3
mejora	I-Claim-Support-3
en	I-Claim-Support-3
el	I-Claim-Support-3
apetito	I-Claim-Support-3
y	I-Claim-Support-3
posiblemente	I-Claim-Support-3
también	I-Claim-Support-3
una	I-Claim-Support-3
reducción	I-Claim-Support-3
de	I-Claim-Support-3
las	I-Claim-Support-3
náuseas	I-Claim-Support-3
y	I-Claim-Support-3
los	I-Claim-Support-3
vómitos	I-Claim-Support-3
,	I-Claim-Support-3
no	I-Claim-Support-3
se	I-Claim-Support-3
pudieron	I-Claim-Support-3
demostrar	I-Claim-Support-3
efectos	I-Claim-Support-3
beneficiosos	I-Claim-Support-3
mensurables	I-Claim-Support-3
del	I-Claim-Support-3
MPA	I-Claim-Support-3
en	I-Claim-Support-3
la	I-Claim-Support-3
calidad	I-Claim-Support-3
de	I-Claim-Support-3
vida	I-Claim-Support-3
.	I-Claim-Support-3

El	B-Premise-Support-1
perfil	I-Premise-Support-1
de	I-Premise-Support-1
efectos	I-Premise-Support-1
secundarios	I-Premise-Support-1
del	I-Premise-Support-1
MPA	I-Premise-Support-1
fue	I-Premise-Support-1
favorable	I-Premise-Support-1
:	I-Premise-Support-1
sólo	I-Premise-Support-1
se	I-Premise-Support-1
observó	I-Premise-Support-1
una	I-Premise-Support-1
tendencia	I-Premise-Support-1
hacia	I-Premise-Support-1
un	I-Premise-Support-1
aumento	I-Premise-Support-1
del	I-Premise-Support-1
edema	I-Premise-Support-1
periférico	I-Premise-Support-1
(	I-Premise-Support-1
normalmente	I-Premise-Support-1
leve	I-Premise-Support-1
)	I-Premise-Support-1
.	I-Premise-Support-1

En	B-Claim
pacientes	I-Claim
con	I-Claim
cáncer	I-Claim
no	I-Claim
sensibles	I-Claim
a	I-Claim
las	I-Claim
hormonas	I-Claim
en	I-Claim
etapa	I-Claim
avanzada	I-Claim
que	I-Claim
están	I-Claim
perdiendo	I-Claim
peso	I-Claim
,	I-Claim
el	I-Claim
MPA	I-Claim
exhibe	I-Claim
un	I-Claim
perfil	I-Claim
de	I-Claim
efectos	I-Claim
secundarios	I-Claim
leves	I-Claim
,	I-Claim
tiene	I-Claim
un	I-Claim
efecto	I-Claim
beneficioso	I-Claim
sobre	I-Claim
el	I-Claim
apetito	I-Claim
y	I-Claim
puede	I-Claim
prevenir	I-Claim
una	I-Claim
mayor	I-Claim
pérdida	I-Claim
de	I-Claim
peso	I-Claim
.	I-Claim

Sin	O
embargo	B-Claim-Partial_Attack--1
,	I-Claim-Partial_Attack--1
la	I-Claim-Partial_Attack--1
calidad	I-Claim-Partial_Attack--1
de	I-Claim-Partial_Attack--1
vida	I-Claim-Partial_Attack--1
general	I-Claim-Partial_Attack--1
en	I-Claim-Partial_Attack--1
el	I-Claim-Partial_Attack--1
presente	I-Claim-Partial_Attack--1
estudio	I-Claim-Partial_Attack--1
no	I-Claim-Partial_Attack--1
se	I-Claim-Partial_Attack--1
vio	I-Claim-Partial_Attack--1
influenciada	I-Claim-Partial_Attack--1
de	I-Claim-Partial_Attack--1
manera	I-Claim-Partial_Attack--1
mensurable	I-Claim-Partial_Attack--1
por	I-Claim-Partial_Attack--1
el	I-Claim-Partial_Attack--1
tratamiento	I-Claim-Partial_Attack--1
con	I-Claim-Partial_Attack--1
MPA	I-Claim-Partial_Attack--1
.	I-Claim-Partial_Attack--1

